Intrinsiqq
Evogene Ltd. logo

Evogene Ltd.

EVGN

Compare

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$4M
EPS-$0.91
P/E-0.33
P/FCF-0.33
EV/EBITDA0.52
FCF Yield–
Div. Yield–
Net Debt/FCF1.0x
Evogene Ltd. intrinsic value
52-Week Range
$0.27$0.89

Profitability & Returns

Revenue (TTM)

$1M

▼ -54.7% YoY

Net Income (TTM)

-$8M

▲ +56.6% YoY

Op. Margin

-1044.30%

▼ -103.3pp YoY

ROIC

-52.94%

▼ -1.3pp YoY

Cash Flow & Balance Sheet

FCF (TTM)

-$11M

▲ +32.9% YoY

Op. Cash Flow (TTM)

-$11M

▲ +21.2% YoY

Net Debt

-$11M

Net Cash Position

Cash & Equiv.

$13M

3Y CAGR: +32.0%

Continue Research

Peers

Biotechnology · Pick stocks to compare with EVGN

CompareIntrinsic value
ALIKO.XPARIkonisys S.A.
€1.54+6.94%30
BLRXBioLineRx Ltd. Sponsored ADR
$0.96-9.43%20
ALTHE.XPARTheraclion S.A.
€0.62+8.19%0
AB.XPARAB Science S.A.
€0.52-7.46%26
ADOC.XPARAdocia SA
€3.29-6.74%10
SXTCChina SXT Pharmaceuticals, Inc.
$2.60+0.39%10
ALPAT.XPARPlant Advanced Technologies S.A.
€3.96-0.50%48
PILA.XSTOPila Pharma AB
€0.13-7.61%10

Evogene (EVGN) in four numbers

Fair value (revenue)
$0.24
Price $0.30 is 27% above it.
Intrinsic Value
Quality score
25/100
Best check: margin trend, +564.1pp. Weakest: return on capital, -52.9%.
Quality
Dividend
None
No dividend in the company filings we hold.
Dividends
P/E
-0.33
Negative: a loss over the last twelve months. Price to free cash flow -0.33.
Financials

Questions about Evogene

Is Evogene (EVGN) overvalued?

At $0.30, Evogene's price is 27% above the $0.24 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.

What is Evogene's fair value?

Intrinsiqq's calculator puts Evogene's fair value at $0.24 a share. It grows revenue per share 6.4% a year for 5 years, applies an exit P/S of 2.6, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $0.18. Every input can be changed on the Intrinsic Value tab.

Is Evogene a high-quality business?

Evogene scores 25 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from company filings. Its best check is margin trend at +564.1pp, and its weakest is return on capital at -52.9%. The Quality tab shows every check against its target.

Does Evogene (EVGN) pay a dividend?

No. Evogene (EVGN) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: company filings. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing EVGN

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.